GoodCap is developing innovative new mushroom-based treatments for physical and mental well-being. With its decades of experience in research and clinical in plant and mycelial biotechnology and developing proprietary and stable plant genetics, GoodCap has brought over one hundred products to market and developed many exclusive formulations and techniques. Currently, GoodCap are targeting inflammation associated with depression through its lead program GCAP001.
GoodCap’s wholly-owned R&D subsidiary Sansero Life Sciences Inc. is currently developing a revolutionary, low-dose psilocybin drug product aimed at displacing antidepressants as a safer and more effective daily solution.
GoodCap
GoodCap aims to be a global leader in the research, development, legal cultivation, and commercialization of mushroom products from their state-of-the-art research facilities in Alberta, Canada.
“Harnessing the powerful medicinal benefits of mushrooms.”
News
- CannaGlobal Appoints World-Class Board and Announces Rebranding to GoodCap Wellness (Business Wire, February 2021).
Activities
B2B
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates